This article discusses the Eli Lilly and Company dispute with Hospira over a generic version of Lilly’s Gemzar®, a cancer drug, with a focus on Lilly’s decision to bring this case to the International Trade Commission (ITC). The ITC is not a typical forum for pharmaceutical companies involved in IP cases. The article states that “in a novel strategy to beat back generic competition to its blockbuster drug Gemzar®, Lilly has turned to the ITC,” a forum that deals with patent disputes in a time sensitive manner. Lilly claims that Hospira has conspired with other drug companies to make a generic form of Gemzar® using a process that infringes it’s patent. Lilly is represented by Finnegan.
Press Release
May 17, 2024
Award/Ranking
Women in Business Law EMEA Awards 2024: Finnegan Nominated for German Firm of the Year
May 15, 2024
Commentary
World IP Day: EPO Reveals 33% Jump in Cleantech Inventions Over Five Years
April 26, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.